CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||100mg/vial and 500mg/vial|
|Indication||Advanced Non-Squamous Non Small Cell Lung Cancer|
|Funding Request||For maintenance following first-line pemetrexed and cisplatin for advanced or metastatic Non Squamous -Non Small Cell Lung Cancer (NS-NSCLC)|
|Pre Noc Submission||No|
|NOC Date||May 9, 2013|
|Manufacturer||Eli Lilly Canada|
|Sponsor||Eli Lilly Canada|
|Submission Date||May 31, 2013|
|Submission Deemed Complete||June 13, 2013|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||June 14, 2013|
|Check-point meeting||August 30, 2013|
|pERC Meeting||October 17, 2013|
|Initial Recommendation Issued||October 31, 2013|
|Feedback Deadline ‡||November 15, 2013|
|Final Recommendation Issued||November 19, 2013|
|Notification to Implement Issued||December 4, 2013|
|Therapeutic Area||Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.